Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2015

Annals of Internal Medicine

Volumn 162, Issue 3, 2015, Pages 214-223

  Kim, David K ^a   Bridges, Carolyn B ^a   Harriman, Kathleen H ^a,b  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; RECOMBINANT VACCINE; VACCINE;

ADULT; ADVISORY COMMITTEE; AGE; ARTICLE; DRUG CONTRAINDICATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLUENZA VACCINATION; MEDICAL SOCIETY; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84922448275     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-2755     Document Type: Article

References (11)

1. Tomcsyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≤65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2014;63;822-5. [PMID: 25233284]
2. Grohskopf LA, Olsen SJ, Sokolow LZ, Bresee JS, Cox NJ, Broder KR, et al Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2014-15 influenza season. MMWR. 2014;63:691-7. [PMID: 25121712]
3. U.S. Food and Drug Administration. October 29, 2014 approval letter-Flublok. Silver Spring, MD: U.S. Food and Drug Administration; 2014. Accessed at www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm421396.htm on 10 December 2014.
4. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network: Streptococcus pneumoniae, 2010. Accessed at www.cdc.gov/abcs/reports-findings/survreports/spneu10.pdf on 10 December 2014.
5. Bonten M, Bolkenbaas M, Huijts S, Webber C, Gault S, Gruber W, et al. Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) [abstract]. Pneumonia. 2014;3:95. Abstract 0541.
6. U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar 13. Silver Spring, MD: U.S. Food and Drug Administration; 2011.
7. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR. 2010;59:1102-6. [PMID: 20814406]
8. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2012;61:816-9. [PMID: 23051612]
9. Williams WW, Lu PJ, O'Halloran A, Bridges CB, Kim DK, Pilishvili T, et al. Noninfluenza vaccination coverage among adults - United States, 2013. MMWR. 2015. [Forthcoming]
10. Miller BL, Kretsinger K, Euler GL, Lu PJ, Ahmed F. Barriers to early uptake of tetanus, diphtheria and acellular pertussis vaccine (Tdap) among adults-United States, 2005-2007. Vaccine. 2011;29:3850-6. [PMID: 21459173]
11. Update on the National Vaccine Advisory Committee Standards for Adult Immunization Practice. 10 September 2013. Accessed at www.hhs.gov/nvpo/nvac/reports/nvacstandards.pdf on 10 December 2014.